PsyAccess
Am I eligible?
Am I eligible?

Press & media

Everything you need to cover PsyAccess without emailing us first, and one address if you want more: hello@psyaccess.health.

Boilerplate

PsyAccess (psyaccess.health) is a verified directory of licensed psychedelic and ketamine/esketamine medicine in Europe: who legally provides treatment, in which country, under which access route (public reimbursement, private care or clinical trial) and what it costs where prices are public. Every record is traced to official sources, most directly to a national registry, and re-verified on a fixed 90-day cycle. Records that cannot be verified are deleted, not published with a warning label. PsyAccess is operated by Pink Elephant, Unipessoal Lda (Lisbon) and is free for patients and providers alike.

A note on terms. We use “psychedelic medicine” as the field's umbrella term. Strictly, ketamine and esketamine are dissociative-class medicines rather than classic psychedelics (our explainer), and classic psychedelics are available in Europe only inside clinical trials, compassionate-use programmes and Switzerland's authorisation scheme. Trial participation is research under a study protocol, not a form of available clinical care. Every record in the directory states which regulatory framework it sits under, and these frameworks differ in both regulation and evidence.

Key facts

Computed from the live catalog on 2026-10-21: these numbers cannot drift from the site, they are the site.

Citable datasets

Each dataset page carries its headline figure, a chart, the methodology, primary sources, a how-to-cite line and an embed snippet. Open CSVs are CC BY 4.0 with attribution; provider-level lists are available on request.

What we can do for journalists and researchers

Custom cuts of the dataset by country, treatment type or access route: same-day for simple requests. Fact-checking of access questions against our primary-source layer (every country fact on the site links to the regulator document it comes from). Comment and background from the medical reviewers listed below, arranged through us. New datasets and reports can be shared under embargo before publication: write with “Embargo” in the subject and your outlet. And corrections: if you find a number on this site that contradicts another number on this site, that is a bug: tell us and it is fixed the same day.

Expert comment: the review board

Members of our review board are available for background and on-the-record comment, arranged through us (hello@psyaccess.health, subject “Press”). Headshots on request.

What PsyAccess is not

We are an informational service, not a healthcare provider, and verification covers licensing and factual claims, never treatment quality or outcomes. We do not rank providers or name a “best” clinic. Listing is free and determined solely by source verification; inclusion is never for sale, and the planned business model is a flat-fee enhanced listing, never per-patient or per-lead fees, never paid placement. PsyAccess takes no pharmaceutical industry money. Coverage depth varies by country: it is strongest where public registries are strongest, and some countries have few listed providers because few licensed providers exist, we say so on the page rather than padding the list.

Assets

Contact

hello@psyaccess.health: mark the subject “Press”. We read everything; press enquiries are answered with priority. PsyAccess is operated by Pink Elephant, Unipessoal Lda, Lisbon, Portugal: legal details on the imprint. Background on the project and the team: /about/; verification model: /methodology/.